Abstract
To determine the effectiveness of quick starting combined oral contraception (COC) contain 2.5 mg nomegestrol acetate and 1.5 mg estradiol (NOMAC/E2) comparing with 0.075 mg gestodene and 0.02 mg ethinyl estradiol (GS/EE) on ovarian ovulation inhibition rate, we conducted a non-inferiority randomized controlled trial involving 69 healthy female volunteers aged 18–40 years who had normal menstrual history and were randomized at a 2:1 ratio to take one pack of COC containing either NOMAC/E2 (study group) or GS/EE (control group) starting on menstrual cycle Day7–9. The ovarian activity was assessed by using Hoogland and Skouby grading. Forty-six and 23 participants were randomized to NOMAC/E2 and GS/EE groups, respectively. Baseline characteristics were similar between groups. No significant difference was observed between the study and control groups for ovulation inhibition rate (93.4% vs. 95.6%, risk difference: –2.2%, 95% CI: –13.1, 8.8), ovarian quiescence rate (91.2% vs. 91.2%, P = 1.000), persistent cyst rate (2.2% vs. 4.4%, P = 1.000), and ovulation rate (6.6% vs. 4.4%, P = 1.000). Quick starting COC during day7–9 of menstrual cycle can inhibit ovulation for more than 90%. The quick starting NOMAC/E2 is non-inferior to GS/EE for preventing ovulation and suppressing follicular growth.
Highlights
Combined oral contraception (COC) is one of the most popular forms contraception because of its high efficacy and accessibility[1]
The present study aimed to determine ovarian activity inhibition associated with Quick starting (QS) COCs containing nomegestrol acetate (NOMAC)/E2 compared with gestodene and 0.02 mg ethinyl estradiol (GS/ethinyl estradiol (EE))
The participants had a mean age of 33.1 ± 5.6 years and mean body mass index (BMI) of 23.4 ± 3.7 kg/M2
Summary
Combined oral contraception (COC) is one of the most popular forms contraception because of its high efficacy and accessibility[1]. Based on our best review, there is little evidence about ovulation inhibition effect of QS of COC use and the emerging information is limited to data from COC containing ethinyl estradiol (EE) with various progestin[8,9,10,11,12,13]. Over several decades since the first introduction of COC, various modalities have been employed to produce COC with better tolerability and less cardiovascular adverse effects without compromising the contraceptive efficacy[14,15,16,17,18,19] These modalities included the application of newer potent progestin, the reduction of EE dosage, and www.nature.com/scientificreports the replacement of EE with a natural estrogen, 17-β estradiol (E2)[20]. The present study aimed to determine ovarian activity inhibition associated with QS COCs containing NOMAC/E2 compared with GS/EE
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
